Cellulose Acetate Beads Activate the Complement System but Inactivate the Anaphylatoxins Generated

Artificial Organs

Volumn 34, Issue 12, 2010, Pages 1144-1149

  Takeda, Yuji ^a,b   Ohba, Masahiro ^b   Ueno, Masamichi ^b   Saniabadi, Abbi R ^b   Wakabayashi, Ichiro ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

Author keywords

Anaphylatoxin; Carboxypeptidase; Complement activation; Extracorporeal circulation; Neutrophil elastase

Indexed keywords

CELLULOSE;

ANAPHYLATOXINS; CARBOXYPEPTIDASE; CELLULOSE ACETATES; COMPLEMENT ACTIVATIONS; COMPLEMENT SYSTEMS; ELASTASE; EXTRACORPOREAL CIRCULATION; NEUTROPHILE ELASTASE; SIDE EFFECT; ZYMOSAN;

CHEMICAL ACTIVATION;

ANAPHYLATOXIN; CARBOXYPEPTIDASE; CELLULOSE ACETATE; ELASTASE; ELASTASE INHIBITOR; ELASTASE INHIBITOR IV; UNCLASSIFIED DRUG; ZYMOSAN;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; APHERESIS; ARTICLE; COLORIMETRY; COMPLEMENT SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; GRANULOCYTE; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SKIN TEST;

EID: 78650067001     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2009.00995.x     Document Type: Article

References (18)

1. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 1995;96:1564-72.
2. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4:133-42.
3. Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007;37:191-200.
4. Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005;20:171-84.
5. Saniabadi AR, Hanai H, Takeuchi K, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003;7:48-59.
6. Chenoweth DE, Henderson LW. Complement activation during hemodialysis: laboratory evaluation of hemodialyzers. Artif Organs 1987;11:155-62.
7. Ivanovich P, Chenoweth DE, Schmidt R, et al. Cellulose acetate hemodialysis membranes are better tolerated than Cuprophan. A difference in complement and neutrophil activation. Contrib Nephrol 1984;37:78-82.
8. Nishise S, Takeda Y, Takeda H, Ishihama K, Fukui T, Kawata S. Complement activation is involved in biological responses to leukocyte adsorptive apheresis. Dig Dis Sci 2006;51:934-41.
9. Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K. Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and β2 integrin. Inflamm Res 2004;53:277-83.
10. Asai S, Sato T, Tada T, et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 2004;173:4669-74.
11. Komura H, Shimomura Y, Yumoto M, Katsuya H, Okada N, Okada H. Heat stability of carboxypeptidase R of experimental animals. Microbiol Immunol 2002;46:217-23.
12. Komura H, Obata K, Campbell W, et al. Effect of anticoagulants in colorimetric assay for basic carboxypeptidases. Microbiol Immunol 2002;46:115-7.
13. Kawamura T, Okada N, Okada H. Elastase from activated human neutrophils activates procarboxypeptidase R. Microbiol Immunol 2002;46:225-30.
14. Yancey KB, Hammer CH, Harvath L, Renfer L, Frank MM, Lawley TJ. Studies of human C5a as a mediator of inflammation in normal human skin. J Clin Invest 1985;75:486-95.
15. Oppermann M, Gotze O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 1994;82:516-21.
16. Rainger GE, Rowley AF, Nash GB. Adhesion-dependent release of elastase from human neutrophils in a novel, flow-based model: specificity of different chemotactic agents. Blood 1998;92:4819-27.
17. Vender RL. Therapeutic potential of neutrophil-elastase inhibition in pulmonary disease. J Investig Med 1996;44:531-9.
18. Ogawa M. Neutrophil elastase. Rinsho-kagaku 1990;26:615-20.